TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06637033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing Food
Description: Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral tube feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral tube feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study: NCT06639555

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP( platelet rich plasma)
Description: regenerative therapy with PRP for vertical bone defects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMD (Enamel Matrix Derivative)
Description: regenerative therapy with EMD for vertical bone defects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration (barrier membrane)
Description: guided tissue regeneration with barrier membrane alone for vertical bone defects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration(barrier membrane and PRP)
Description: guided tissue regeneration with barrier membrane and PRP for vertical bone defects
Study: NCT06636851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and defibrillator
Description: Permenant pacemaker implantation with lead fixed to the RV Septal location

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and defibrillator
Description: Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
Study: NCT06643208

Intervention type: DRUG
Intervention: TACE-HAIC, Envafolimab and Lenvatinib
Description: TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
Study: NCT06643546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theoretical training
Description: received only theoretical breastfeeding training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model simulation training
Description: theoretical breastfeeding training and model simulation training accompanied by scenarios

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: live-simulation
Description: theoretical breastfeeding training and live simulation training with scenarios
Study: NCT05406453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing testing
Description: Whole Genome Sequencing testing, community-based contact tracing
Study: NCT04457154

Intervention type: DEVICE
Intervention: Inspire Upper Airway Stimulation System
Description: Implant of the Inspire Upper Airway Stimulation System
Study: NCT06211049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitex agnus-castus BNO 1095 (20 mg)
Description: 1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
Study: NCT06113198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: 3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
Study: NCT04846699

Intervention type: PROCEDURE
Intervention: per-cutaneous stone extraction
Description: percutaneous nephrolithotripsy for renal stones by different renal access

Intervention type: PROCEDURE
Intervention: per-cutaneous stone extraction
Description: percutaneous nephrolithotripsy for renal stones by different renal access

Intervention type: PROCEDURE
Intervention: per-cutaneous stone extraction
Description: percutaneous nephrolithotripsy for renal stones by different renal access
Study: NCT05756621

Intervention type: DRUG
Intervention: Ketamine
Description: Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution.

Intervention type: DRUG
Intervention: Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
Description: Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
Study: NCT06200779

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test
Description: Described in Arms section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
Description: Described in Arms section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy (Pylera®) for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
Study: NCT06439407

Intervention type: DEVICE
Group type: OTHER
Intervention: SAT-014(Software as Medical Device)
Description: SAT-014(Software as Medical Device) + maintain previous treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-014(Software as Medical Device)
Description: SAT-014(Software as Medical Device) + maintain previous treatment
Study: NCT06521567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Cobolimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Cobolimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered
Study: NCT06651970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Acalabrutinib Monotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Investigator's choice of treatment
Description: control arm treatment type will be defined by the PI prior to randomisation
Study: NCT04816903

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gyni
Description: Vaginal discharge collection
Study: NCT05671887

Intervention type: PROCEDURE
Intervention: Double Lung Transplantation
Description: To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Intervention type: PROCEDURE
Intervention: Double Lung Transplantation
Description: To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Intervention type: PROCEDURE
Intervention: Double Lung Transplantation
Description: To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
Study: NCT06367972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Next-line Systemic Therapy
Description: The specific next-line systemic therapy will be determined by your doctor.
Study: NCT05940324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is an FDA-approved dissociative anesthetic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine is an FDA-approved dissociative anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
Study: NCT06659744

Intervention type: DRUG
Intervention: New use of semaglutide injection
Description: New use of semaglutide injection dispensing claim is used as the exposure.

Intervention type: DRUG
Intervention: New initiation of sitagliptin
Description: New initiation of sitagliptin dispensing claim is used as the reference.
Study: NCT06010836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script guided conversation
Description: Patients getting script guided intervention of 3 domains in the preoperative period
Study: NCT05877326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with propofol or sevoflurane
Description: General anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with propofol or sevoflurane
Description: General anesthesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative
Description: The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative
Description: The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
Study: NCT05698316

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of both retrospective and prospective data collection in 3 visits.
Description: 3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
Study: NCT05775120

Intervention type: DIAGNOSTIC_TEST
Intervention: OLGA and H.pylori culture
Description: Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
Study: NCT06333158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesfytol NG
Description: 3 capsules a day with dinner.
Study: NCT04288193

Intervention type: DRUG
Intervention: Recommendation to Deprescribe
Description: Recommendation to Deprescribe
Study: NCT06333158

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules a day with dinner
Study: NCT06664853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
Study: NCT06530615

Intervention type: PROCEDURE
Intervention: Bronchoalveolar Lavage (BAL) during Bronchoscopy
Description: Bronchoalveolar Lavage (BAL) is a standard diagnostic tool for the evaluation of lower respiratory tract pathology including respiratory infections and unexplained radiographic pulmonary lesions including lung neoplasia. It is a minimally invasive procedure that involves introduction of the bronchoscope, installation of sterile normal saline into a subsegment of the lung, and suction and collection of the recovered saline for diagnostic evaluation.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar Lavage (BAL) during Bronchoscopy
Description: Bronchoalveolar Lavage (BAL) is a standard diagnostic tool for the evaluation of lower respiratory tract pathology including respiratory infections and unexplained radiographic pulmonary lesions including lung neoplasia. It is a minimally invasive procedure that involves introduction of the bronchoscope, installation of sterile normal saline into a subsegment of the lung, and suction and collection of the recovered saline for diagnostic evaluation.
Study: NCT05465174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally
Study: NCT06672666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemp Derived Cannabidiol Extract
Description: Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
Study: NCT06671262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy
Description: Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy
Description: Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immuno-chemotherapy
Description: Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
Study: NCT06545825

Intervention type: OTHER
Intervention: Standard enteral nutrition
Description: Enteral nutrition will be given with standard isocaloric mixtures. Mixture volume calculation will be performed after indirect calorimetry, adjusted for daily nitrogen loss.
Study: NCT05595499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06679400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Description: Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage.
Study: NCT06684457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Education
Description: Atrial fibrillation education rendered through a generative AI chatbot, using an iPAD. The intervention itself is an approximately 1 hour long interaction with the chatbot or approximately 10 questions about atrial fibrillation, for 1 single interaction.
Study: NCT06691672

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Robotic Tomographic ultrasound imaging of the arm vasculature.
Description: Semi-autonomous robotic tomographic ultrasound imaging of the arm vasculature for vascular access creation mapping in CKD patients.
Study: NCT06692764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg (Placebo). Participants will receive bottles, with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose.
Study: NCT05120349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.